AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

AstraZeneca said the “cornerstone” of the commitment would be a new weight management production facility for its oral GLP-1 ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...